Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. - Wikidata - awgldk - TriplyDB

Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.

Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.

http://www.wikidata.org/entity/Q37026639

about

Use of rifaximin in gastrointestinal and liver diseases Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection The potential for emerging therapeutic options for Clostridium difficile infection Conventional and alternative treatment approaches for Clostridium difficile infection Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Using a Novel Lysin To Help Control Clostridium difficile Infections Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.Therapies on the horizon for Clostridium difficile infections.Rifamycins, Alone and in Combination.Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin.Novel Antimicrobials for the Treatment of Clostridium difficile Infection.

P2860

Q26740201-56BE9857-D439-4B51-A95F-07A17E0A2D4B Q26767079-6CEAE54C-7F59-4AC4-9F03-DD29A61A504D Q28082059-B72369DD-A05D-4F9A-B859-B1CF17C60216 Q30235278-FEDDB9B2-C2F4-4CF3-A579-89BEA5FB34EB Q35044119-2849929B-4D66-4C5C-8A98-05F29A4B960E Q36290571-C5204454-6181-4DDA-959D-1E198505D45D Q37203899-2377FAAE-41B5-47F9-80B2-1B84EE385E27 Q38692607-F8103303-33E6-4300-B522-FB4089E43454 Q38757930-55D170DF-4949-45CE-9865-0215F8440750 Q38857578-B5356D8C-C641-42B7-BEA3-962A665A59D7 Q50082624-8D98D37C-7906-47AD-8B62-11659283B9EC Q55405974-A6C9B04C-AFD5-4FBA-835D-AF974E31FDE6

P2860

Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.

http://www.wikidata.org/entity/Q37026639

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Use of rifamycin drugs and dev ...... ains of Clostridium difficile.

@en

Use of rifamycin drugs and dev ...... ains of Clostridium difficile.

@nl

type

label

Use of rifamycin drugs and dev ...... ains of Clostridium difficile.

@en

Use of rifamycin drugs and dev ...... ains of Clostridium difficile.

@nl

prefLabel

Use of rifamycin drugs and dev ...... ains of Clostridium difficile.

@en

Use of rifamycin drugs and dev ...... ains of Clostridium difficile.

@nl

P1433

Q37026639-67D71B99-4649-4B96-80D6-968A280FDA8F

P1476

Q37026639-F3B10BAA-2EB6-46E0-B40A-36D38EFB10E6

P2093

Q37026639-83B8FB29-D314-4542-863F-6C0544E77B4B

Q37026639-99D69547-6D49-4B89-9B81-0680891B93B8

Q37026639-9A651427-9711-4264-A647-4D92008B5ABB

Q37026639-C608FB09-91FB-4CE0-B1ED-B680ACD3A81B

P2860

Q37026639-2947D018-49C8-4671-882B-026DA7653A6F

Q37026639-4096B52E-856F-407A-AF12-1D320395629E

Q37026639-4295F533-C50A-4BDB-92AC-D45464B43F75

Q37026639-54FDE671-9F70-4048-994B-597A0D147CCA

Q37026639-5A7CFEB4-101F-4CC6-9828-4DF3672DE3D7

Q37026639-70FF3C2D-EE96-42FF-BB98-3E1A756D0AB7

Q37026639-7601788C-3C3E-4D29-B740-476B04752940

Q37026639-7BA62AE3-AA78-49C5-8B5D-11622250DDAD

Q37026639-7D8FD6B4-8D26-4C4C-8B54-7FD34C0F2F24

Q37026639-84260680-10B4-4783-B6ED-7007C0C440CC

P304

Q37026639-03DD4387-93B0-49C0-8573-7C3E5B9D6063

P31

Q37026639-2D9E6B76-59C8-4278-A481-6FA66D9BFE64

P356

Q37026639-4286C641-B879-422C-A858-4638B597E481

P407

Q37026639-1964BD5F-D100-440C-8675-55566903C66A

P433

Q37026639-E078C856-4438-4101-A858-56D4F2D2B465

P478

Q37026639-31000425-FF70-4993-BE9C-C01E3C68DE13

P50

Q37026639-7D4D683E-981A-4FF2-9592-A868E66683A9

P577

Q37026639-78811BC6-97F5-4573-B747-CF897C6D2C6D

P698

Q37026639-ED390629-BE2E-48A7-BDED-B983FAA0C41C

P921

Q37026639-DD76F349-03FE-4B9C-B0AD-4C3C6F4682A1

P932

Q37026639-A99C4272-6DBE-4C0A-A76E-785A74C6A797

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Use of rifamycin drugs and dev ...... rains of Clostridium difficile

@en

P2093

Herbert L Dupont

http://www.w3.org/2001/XMLSchema#string

Jamie S Huang

http://www.w3.org/2001/XMLSchema#string

Todd Lasco

http://www.w3.org/2001/XMLSchema#string

Zhi-Dong Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis

Rifaximin treatment in hepatic encephalopathy

Rifaximin therapy for patients with irritable bowel syndrome without constipation

Mapping and sequencing of mutations in the Escherichia colirpoB gene that lead to rifampicin resistance

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.

Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis.

P304

2690-2693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00548-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23545528

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

P932

3716149

http://www.w3.org/2001/XMLSchema#string